Biscran-D Liquid Filled Capsule

Recurrent UTI (Urinary Tract Infection) is one of the most prevalent and undertreated conditions affecting women in India — particularly those with diabetes, post-coital susceptibility, peri/post-menopausal status, or a history of repeated episodes. Conventional antibiotic prophylaxis carries the burden of resistance development, microbiome disruption, and long-term compliance challenges.

Biscran-D offers a clinically validated, antibiotic-free solution: three oil-based actives with distinct and complementary mechanisms of action, delivered in a technologically superior liquid filled capsule system that maximizes bioavailability and therapeutic impact — making it the most potent prophylactic option for UTI recurrence currently available in the Indian market.

The Capsule Technology Advantage — Why Liquid Filled Matters

Biscran-D is formulated as a Liquid Filled Band Sealed Hard Shelled Capsule (HPMC) — a pharmaceutical technology with significant advantages over conventional powder-filled or extract-based capsules:

• Vegetarian capsule made from HPMC (Hydroxy Propyl Methyl Cellulose) — no animal-derived gelatin
• No plasticizers that can migrate into the drug product and affect stability or safety
• Disintegrates faster due to thin capsule wall — offering enhanced bioavailability and improved product stability
• Low moisture intake — suitable for moisture-sensitive oil formulations like cranberry and tea tree oils
• Low permeability effectively masks the taste and odour of active oils — significantly improving patient compliance
• Band sealing prevents leakage and makes the capsule tamper-proof — ensuring product integrity
• Oil formulation: 5× more potent than equivalent extract or powder dosage forms

The Three Active Ingredients — Individual and Combined Mechanisms

Cranberry Oil 300 mg

• Reduces urine pH through phenolic content — increasing bacteriostatic property against common UTI pathogens
• Urine acidification enhances production of nitric oxide — which exerts direct antimicrobial action
• Inhibits adherence of uropathogens to urinary tract epithelium — preventing the first and most critical step in UTI pathogenesis (bacterial colonization)
• Reduces bacterial colonization in the bladder, urethra, and ureter

D-Mannose 100 mg

• An inert monosaccharide that is as effective as antibiotic therapy at reducing recurrent UTI — without carrying any antibiotic resistance risk
• Improves quality of life by reducing the frequency, severity, and psychological burden of recurrent UTI symptoms
• Attaches to E-Coli bacteria — the primary UTI causative pathogen — so that bacteria cannot take up residence in the urethra, bladder, or ureter
• Works by competitive inhibition — E-Coli binds to D-Mannose in the urine rather than to the urothelial surface, and is then flushed out with urination

Tea Tree Oil 100 mg

• Does not kill good bacteria (Lactobacillus) — preserving the natural vaginal and urinary microbiome that acts as the first line of defence against UTI pathogens
• Selectively suppresses the growth of pathogenic E-Coli — the organism responsible for over 80% of UTI cases
• Ideal for long-term UTI prevention without the microbiome disruption associated with antibiotics

The Power of Combining All Three

When Cranberry Oil and D-Mannose are combined — as in Biscran-D — clinical evidence demonstrates:

• Adjuvant effect for empirical UTI treatment — the combination is more effective than either alone
• Antibiotic potentiating effect — when used alongside antibiotics, Biscran-D enhances their efficacy against uropathogens
• Enhances sensitivity of uropathogens to antimicrobial treatment — a significant clinical advantage in MDRO cases
• Tea Tree Oil adds selective pathogen suppression without disrupting Lactobacillus — completing the three-layer protective mechanism

Clinical Indications

• Asymptomatic bacteriuria in pregnancy — safe, antibiotic-free management
• Recurrent cystitis — primary prophylactic therapy
• Pyelonephritis — adjuvant to standard antimicrobial therapy
• Post-coital infection — single-dose prophylaxis for susceptible women
• Recurrent UTI in diabetics — safe long-term use without glycaemic impact
• Peri/post-menopausal women — addresses the elevated UTI susceptibility associated with estrogen decline
• Patients seeking to reduce antibiotic exposure and resistance risk

Why Biscran-D is a Clinical Game-Changer

• First-in-India oil-based UTI prophylaxis — no comparable product exists in the Indian market
• 5× more potent than extract or powder equivalent dosages
• Three complementary mechanisms — adhesion inhibition, competitive displacement, selective pathogen suppression
• Preserves healthy microbiome — unlike antibiotic prophylaxis
• 1 capsule per day — maximum convenience and compliance
• Vegetarian, band-sealed, tamper-proof capsule technology
• Supported by published peer-reviewed clinical references

Composition